Skip to content

Alexander Bryson

9 papers in the library · 27 citations · publishing 2017-2026

Papers

Sort Most recent Most cited

After the Trip: A Qualitative Study of Healthy Individuals' Motor Experiences Following Different Doses of Psilocybin.

Brain and Behavior October 2026 Ruiqi Rachel Luo, David J. Berlowitz, Alexander Bryson et al.

Psilocybin is a naturally occurring classic psychedelic associated with widespread changes in brain function and promising therapeutic outcomes in several neuropsychiatric disorders. Complementing these findings, qualitative studies following psilocybin administration have revealed diverse and highly individual effects across multiple domains of subjective experience. However, little is known...

DOI: 10.1002/brb3.71807 (opens in new tab) Full text (opens in new tab) Psilocybin Motor function Subjective experiences Thematic analysis

Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study

CNS Drugs August 7, 2026 Chiranth Bhagavan, Olivia Carter, Glenn Nielsen et al.

BACKGROUND: Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers....

Psilocybin’s kinematic effect on manual dexterity

Psychopharmacology June 17, 2026 Pierre Klintefors, Chiranth Bhagavan, Richard Kanaan et al.

RATIONALE: Clinical interest in psilocybin-assisted rehabilitation for motor disorders is growing. However, psilocybin's motor effects are under-researched, and quantifying them is essential for assessing treatment risks and outcomes. OBJECTIVES: This study aims to clarify whether acute effects of psilocybin disrupt established patterns of manual dexterity and coordination. Specifically, we...

DOI: 10.1007/s00213-026-07106-8 (opens in new tab) Psilocybin Kinematics Rehabilitation Task project management +2

Sustained Effects of Low-to-Moderate Doses of Psilocybin on Brain Connectivity

medRxiv Preprint Server April 17, 2026 Chiranth Bhagavan, Orwa Dandash, Olivia Carter et al. preprint

Background Psilocybin is a classic psychedelic that acutely alters brain functional connectivity. These changes are linked to therapeutic doses and subjective effects, with some evidence that changes persist beyond acute drug administration. However, the effects of lower doses on sustained connectivity changes remain unclear.

Psychedelics in functional disorders: A scoping review

Progress in Neuro-Psychopharmacology and Biological Psychiatry February 10, 2026 Chiranth Bhagavan, Olivia Carter, Alexander Bryson et al. 1 citation

Functional disorders, characterised by symptoms unexplained by organic disease, impose a significant burden on individuals and healthcare systems. Existing treatments are limited in efficacy, with no effective pharmacotherapies. There is growing evidence supporting the treatment potential of psychedelics in neuropsychiatric conditions, including several distinct functional disorders. This...

DOI: 10.1016/j.pnpbp.2026.111642 (opens in new tab) Observational study Clinical trial Functional impairment Medline +4

A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants

medRxiv December 23, 2025 Chiranth Bhagavan, Olivia Carter, Glenn Nielsen et al. 1 citation preprint

Abstract Background Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study’s primary objectives examined the feasibility and safety of administering movement tasks following low-to-moderate doses of...

Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study

Acta Neuropsychiatrica November 4, 2025 Chiranth Bhagavan, Alexander Bryson, Olivia Carter et al. 4 citations

Abstract Background: Motor functional neurological disorder (FND) is a common illness associated with significant functional impairment. There are no effective pharmacotherapies, and despite the early promise of physiotherapy studies, many suffer disabling symptoms in the long term. There is a theoretical rationale for combining psychedelics with physiotherapy; however, the potential benefit of...

DOI: 10.1017/neu.2025.10042 (opens in new tab) Full text (opens in new tab) Protocol science Refractory planetary science Pilot trial Randomized controlled trial +7

Psilocybin and Motor Function: A Triple‐Blind, Dose‐Finding Study in Healthy Participants

Psychiatric Research and Clinical Practice July 23, 2024 Chiranth Bhagavan, Richard Kanaan, Olivia Carter et al. 2 citations

Background There has been a resurgence of research into the potential therapeutic benefits of psychedelics for neuropsychiatric disorders. Classic psychedelics, such as psilocybin, exert complex effects on higher cognitive functions such as perception and awareness, but their impact on motor function remains unexplored. Moreover, there is a theoretical rationale for using psychedelics to...

DOI: 10.1176/appi.prcp.20240047 (opens in new tab) Psilocybin Hallucinogen Cognition Subliminal stimuli +3

5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?

The International Journal of Neuropsychopharmacology February 8, 2017 Alexander Bryson, Olivia Carter, Trevor R. Norman et al. 19 citations

Functional neurological disorders are frequently encountered in clinical practice. They have a poor prognosis and treatment options are limited. Their etiology is unknown, but leading theories propose a disturbance of somatic self-representation: the mind perceives dysfunction of a body region despite intact motor and sensory pathways. Central to this model is the concept of an abnormal...

DOI: 10.1093/ijnp/pyx011 (opens in new tab) Full text (opens in new tab) Cognition Genetic neurodegenerative diseases